Enter assignee name

Trademarks = 1

Forward Citations = 0

Loading Chart...

23 inventors (with patents filed for the assignee):

Marc J Lajoie (3 out of 18 patents)

Spencer Park (2 out of 2 patents)

Queenie Vong (2 out of 2 patents)

4. Blythe Sather (2 out of 2 patents)

5. Byoung Ryu (2 out of 2 patents)

6. Nicholas P Restifo (2 out of 2 patents)

7. Scott Edward Boyken (2 out of 2 patents)

8. Howell Franklin Moffett (2 out of 2 patents)

9. Suman Kumar Vodnala (1 out of 2 patents)

10. Naritaka Tamaoki (1 out of 1 patent)

11. Viola Lam (1 out of 1 patent)

12. Rachel Christina Lynn (1 out of 1 patent)

13. Shobha Potluri (1 out of 1 patent)

14. Neeraj Sharma (1 out of 1 patent)

15. Bijan Boldajipour (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 12679879 - NR4A-DEFICIENT CELLS EXPRESSING C-JUN AND USES THEREOF (2026-07-14),

2. 12365871 - Methods for culturing cells (2025-07-22),

3. 12270032 - Codon-optimized nucleotide sequences encoding an AP-1 transcription factor (2025-04-08),

4. 12144827 - ROR1 targeting chimeric antigen receptor (2024-11-19),

5. 12091682 - Methods for making, compositions comprising, and methods of using rejuvenated T cells (2024-09-17),

6. 12054531 - Recombinant cell surface markers (2024-08-06),

Lyell Immunopharma, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company aims to harness the power of the immune system to create effective therapies that can overcome the limitations of traditional cancer treatments. Lyell's proprietary technology platform is designed to enhance the persistence and functionality of T cells, enabling them to better target and eliminate cancer cells. With a strong emphasis on research and development, Lyell is committed to advancing its pipeline of therapies to improve patient outcomes in oncology.

Profile summary based on public USPTO records.